The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 4: 588 - 593

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.04.019

Drugs and Clinic Practice

Study on the relationship between UGT1A1 polymorphism and UGT1A1 inhibitory drugs⁃induced liver injury

  • Yujia LU ,
  • Keying OU ,
  • Yueyang MA ,
  • Chuansu YUAN ,
  • Bin LIU ,
  • Yongfeng YANG ,
  • Qingfang. XIONG
Expand
  • 1.Department of Hepatology，Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine/Nanjing Second Hospital，Nanjing 210003，Jiangsu，China
    3.The Clinical Infectious Disease Center of Nanjing，Nanjing 210003，Jiangsu，China

Received date: 2024-11-08

  Online published: 2025-02-28

Fold

Abstract

Objective To investigate the association between UGT1A1 inhibitors-induced liver injury （DILI） and UGT1A1 gene polymorphisms through a pharmacogenomics approach. Methods Information on relevant drugs that may induce liver injury， blood routine tests， and liver function tests was collected from hospitalized patients diagnosed with DILI between June 2022 and June 2024. Relevant databases were searched to categorize DILI-associated drugs into UGT1A1 enzyme inhibitors and those without interaction with UGT1A1. Sanger sequencing or MassARRAY SNP typing technology was utilized to detect and genotype the UGT1A1 gene. Results A total of 219 patients with drug-induced liver injury （DILI） were enrolled， including 98 males， with a mean age of 46.32 ± 14.95 years. A literature search of relevant databases revealed that 20 drugs （16.26%， 20/123） associated with DILI had inhibitory effects on the UGT1A1 enzyme. The proportion of DILI cases related to UGT1A1 inhibitors was 60.73% （133/219）. Compared to non-UGT1A1 inhibitor-related DILI group， the UGT1A1 inhibitor-related DILI group exhibited significantly higher levels of ALT， AST， ALP， and GGT （P < 0.05）， while no significant differences were observed in age， gender， TBIL， IBIL， WBC， Hb， PLT， injury type， or injury grade （P > 0.05）. The prevalence of UGT1A1 polymorphisms was significantly higher in the UGT1A1 inhibitor-related DILI group （68.42%） compared to the non-UGT1A1 inhibitor-related DILI group （51.16%）， with an odds ratio （OR） of 2.068 （95% CI： 1.183 to 3.617； χ2 = 6.58， P = 0.010）. There was also a significant difference in the distribution of genotypes between the UGT1A1 inhibitor-related and non-UGT1A1 inhibitor-related DILI groups （χ2 = 9.60， P = 0.022）. Univariate logistic regression analysis indicated that ALT and UGT1A1*6 were associated with UGT1A1 inhibitor-related DILI， while multivariate analysis confirmed that UGT1A1*6 was independently associated with UGT1A1 inhibitor-related DILI ［OR（95%CI） = 3.143 （1.398 to 7.067）， P = 0.006］. Conclusion The UGT1A1*6 allele increases the susceptibility to drug-induced liver injury （DILI） associated with UGT1A1 inhibitory drugs.

Key words： drug-induced liver injury; gene polymorphism; UGT1A1; drug; inhibitor

Cite this article

Yujia LU , Keying OU , Yueyang MA , Chuansu YUAN , Bin LIU , Yongfeng YANG , Qingfang. XIONG . Study on the relationship between UGT1A1 polymorphism and UGT1A1 inhibitory drugs⁃induced liver injury[J]. The Journal of Practical Medicine, 2025 , 41(4) : 588 -593 . DOI: 10.3969/j.issn.1006-5725.2025.04.019

References

1 DEVARBHAVI H， AITHAL G， TREEPRASERTSUK S， et al. Asia Pacific Association of Study of Liver.Drug-induced?liver?injury： Asia Pacific Association of Study of?Liver?consensus?guidelines［J］.Hepatol Int， 2021，15（2）：258-282. doi:10.1007/s12072-021-10144-3
2 CHALASANI N P， MADDUR H， RUSSO M W， et al. ACG Clinical Guideline： Diagnosis and Management of Idiosyncratic?Drug-Induced?Liver?Injury［J］.Am J Gastroenterol， 2021，116（5）：878-898. doi:10.14309/ajg.0000000000001259
3 BRENNAN P N， CARTLIDGE P， MANSHIP T， et al. Guideline review： EASL clinical practice?guidelines：?Drug-induced?liver?injury?（DILI）［J］.Frontline Gastroenterol， 2021，13（4）：332-336. doi:10.1136/flgastro-2021-101886
4 中国医药生物技术协会药物性肝损伤防治技术专业委员会， 中华医学会肝病学分会药物性肝病学组.中国药物性肝损伤诊治指南（2023年版）［J］. 中华肝脏病杂志， 2023， 31（4）： 355-384.
5 KALIYAPERUMAL K， GROVE J I， DELAHAY R M， et al. Pharmacogenomics?of?drug-induced?liver?injury?（DILI）： Molecular biology to clinical applications［J］.J Hepatol， 2018，69（4）：948-957. doi:10.1016/j.jhep.2018.05.013
6 李娟，陈冰，张伟霞.UGT1A1遗传多态性与非遗传因素对伊立替康不良反应影响的回顾分析［J］.中国医院药学杂志，2024，44（24）：2863-2867，2880. doi:10.13286/j.1001-5213.2024.24.10
7 SHAO Q， MAO X， ZHOU Z， et al. Research Progress of Pharmacogenomics in?Drug-Induced?Liver?Injury［J］.Front Pharmacol， 2021，12：735260. doi:10.3389/fphar.2021.735260
8 KIM S， KIM D K， SHIN Y， et al. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450， UDP-Glucuronosyltransferase Enzymes and Drug Transporters［J］. Molecules， 2020，25（19）：4589. doi:10.3390/molecules25194589
9 熊清芳，陆雨佳，邹磊， 等. 遗传性高非结合性胆红素血症患者的UGT1A1基因突变谱和临床表型的关系［J］. 中华肝脏病杂志， 2024，32（4）：340-345. doi:10.3760/cma.j.cn501113-20230830-00081
10 OLUBAMIWA A O， LIAO T J， ZHAO J， et al.Drug?interaction?with?UDP-Glucuronosyltransferase?（UGT）?enzymes?is a predictor of?drug-induced liver injury［J］.Hepatology， 2024. doi： 10.1097/HEP.0000000000001007 . Epub ahead of print.
11 闫媛，李慧慧，彭佩瑾，等. 中药成分对肝脏尿苷二磷酸葡萄糖醛酸转移酶的体外作用研究进展［J］. 中国中药杂志，2024，49（20）：5397-5409.
12 马雄，王绮夏，肖潇，等. 自身免疫性肝炎诊断和治疗指南（2021）［J］. 临床肝胆病杂志，2022，38（1）：42-49. doi:10.3760/cma.j.cn112138-20211112-00796
13 NAKAMURA R， ARAKAWA N， TANAKA Y， et al.Significant association between HLA-B*35：01 and onset of?drug-induced?liver?injury?caused by Kampo medicines in Japanese patients［J］.Hepatol Res， 2023，53（5）：440-449. doi:10.1111/hepr.13874
14 HUANG Y S， TSENG S Y， CHANG T E， et al. Sulfamethoxazole-trimethoprim-induced?liver?injury?and?genetic?polymorphisms of NAT2 and CYP2C9 in Taiwan［J］.Pharmacogenet Genomics， 2021，31（9）：200-206. doi:10.1097/fpc.0000000000000441
15 WANG C W， PRECLARO I A C， LIN W H， et al. An Updated Review of?Genetic?Associations With Severe Adverse?Drug?Reactions： Translation and Implementation of Pharmacogenomic Testing in Clinical Practice［J］. Front Pharmacol， 2022，13：886377. doi:10.3389/fphar.2022.886377
16 DE MATTIA E， CECCHIN E， POLESEL J，et al. UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population ［J］. Liver Int， 2017，37（9）：1345-1353. doi:10.1111/liv.13411
17 SINGH S， KUMAR P V S N K， KUMAR J P， et al. Genetic?and Epigenetic Basis of?Drug-Induced?Liver?Injury［J］. Semin Liver Dis， 2023，43（2）：163-175. doi:10.1055/a-2097-0531
18 李娟娟，何婷，魏亚利，等. 药物性肝损伤中miR-122的动态表达研究进展［J］. 实用医学杂志，2022，38（24）：3167-3170.
19 钟洪兰. 抗结核药物致肝损伤的预防与治疗药物选择［J］. 实用医学杂志，2020，36（24）：3307-3311.
20 L?NNBERG K I， TORNIO A， HIRVENSALO P， et al. Real-world pharmacogenetics of statin intolerance： Effects of SLCO1B1， ABCG2， and CYP2C9 variants［J］. Pharmacogenet Genomics， 2023，33（7）：153-160.
21 ZHAO H D， BAO G Q， HE X L， et al. Strong Inhibition of UDP Glucuronosyltransferase（UGT） 1A1 by Levothyroxine Indicates the Potential UGT-Inhibition Based Adverse Effect of Levothyroxine［J］. Lat Am J Pharm， 2012， 31（5）， 761-763.
22 张丹丹，徐峰，李娅，等. 糖皮质激素对重症药物性肝损伤的疗效分析及剂量选择［J］. 实用医学杂志，2023，39（6）：747-751. doi:10.3969/j.issn.1006-5725.2023.06.016
23 KOIDO M， KAWAKAMI E， FUKUMURA J，et al. Polygenic architecture informs potential vulnerability to?drug-induced?liver?injury［J］. Nat Med， 2020，26（10）：1541-1548. doi:10.1038/s41591-020-1023-0
24 ALSHABEEB M， ALOMAR F A， KHAN A. Impact of SLCO1B1*5 on Flucloxacillin and Co-Amoxiclav-Related?Liver?Injury［J］. Front Pharmacol， 2022，13：882962. doi:10.3389/fphar.2022.882962
25 ST?TTERMAYER A F， HALILBASIC E， WRBA F， et al. Variants in ABCB4 （MDR3） across the spectrum of cholestatic?liver?diseases in adults［J］. J Hepatol， 2020，73（3）：651-663. doi:10.1016/j.jhep.2020.04.036
26 HOU X D， SONG L L， CAO Y F， et al. Pancreatic lipase inhibitory constituents from Fructus Psoraleae［J］. Chin J Nat Med， 2020，18（5）：369-378. doi:10.1016/s1875-5364(20)30043-1
Options
Outlines

/

〈 〉